Facilitating the Behavioral Treatment of Cannabis Use Disorder
Brief Summary
Cannabis use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered cannabis use. Cannabis use disorders are recognized to be associated with various vulnerabilities that complicate the course of treatment and that may be amenable to glutamate modulators. The purpose of this single blind open-label trial is to test the feasibility of administering glutamate modulators in conjunction with motivational enhancement therapy (MET) and mindfulness based relapse prevention (MBRP) for cannabis use disorders.
Study Design
| Study type: | Interventional |
|---|---|
| Status: | Completed |
| Study results: | Has Results |
| Age: | 21 Years to 60 Years (Adult) |
| Enrollment: | 8 () |
| Funded by: | Other|NIH |
Masking |
|
Clinical Trial Dates
| Start date: | Oct 16, 2020 | |
|---|---|---|
| Primary Completion: | Aug 18, 2020 | |
| Completion Date: | Aug 18, 2020 | |
| Study First Posted: | Oct 27, 2016 | |
| Results First Posted: | Feb 11, 2020 | |
| Last Updated: | Feb 11, 2020 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
Individuals diagnosed with cannabis dependence will receive one or two infusions of glutamate modulators during week 2 and week 3 or 4. The participants will also receive 2-week course of MET and 4-week course of MBRP. Participants will meet with staff twice weekly, except for week 2 and potentially week 3 or 4 during which participants will present to the clinic three times. Clinic visits include MET sessions, MBRP sessions, psychiatric monitoring, assessments, and study procedures (e.g., medication administration).
Eligibility Criteria
| Sex: | All |
|---|---|
| Minimum Age: | 21 |
| Maximum Age: | 60 |
More Details
| NCT Number: | NCT02946489 |
|---|---|
| Other IDs: | 7355|K24DA029647 |
| Study URL: | https://ClinicalTrials.gov/show/NCT02946489 |
Last updated: Jan 27, 2021